Table 2.
Responsesa of cervical tumor to indicated treatment.
| Triapine–cisplatin–radiation | Cisplatin–radiation | Cisplatin-alone | Radiation-alone | |
|---|---|---|---|---|
| Cisplatin dose (frequency) | 40 mg m−2 (x1 weekly) | 30 mg m−2 (x1 weekly) | 50 mg m−2 (q3 weeks) | Placebo |
| Evaluable | 29 | 50 | 150 | 43 |
| Clinical complete response (CR) | 29 (100%) | 44 (88%) | 15 (10%) | 21 (49) |
| Clinical partial response (PR) | 0 (0%) | 6 (12%) | 16 (11%) | 7 (16%) |
| Clinical stable disease | 0 (0%) | 0 (0%) | 60 (40%) | 7 (16%) |
| Clinical progressive disease | 0 (0%) | 0 (0%) | 59 (39%) | 8 (19%) |
| All clinical responses (CR + PR) | 24 (100%) | 50 (100%) | 31 (21%) | 28 (65%) |
| Reference | (31, 32) | (37) | (38) | (39) |
| Cisplatin dose (frequency) | 40 mg m−2 (x1 weekly) | 40 mg m−2 (x1 weekly) | ||
| Evaluable | 22 | 238 | ||
| Metabolic complete response (mCR) | 21 (95%) | 173 (73%) | ||
| Metabolic partial response (mPR) | 1 (4%) | 40 (17%) | ||
| Metabolic stable disease | 0 (0%) | 0 (0%) | ||
| Metabolic progressive disease | 0 (0%) | 25 (10%) | ||
| All metabolic responses (mCR + mPR) | 22 (100%) | 213 (89%) | ||
| Reference | (31, 32) | (40) |
FDG PET, 18F-fluorodeoxyglucose positron emission tomography.
aResponse Evaluation Criteria in Solid Tumors, version 1.0.